25 XP   0   0   10

Abbott Laboratories
Buy, Hold or Sell?

Let's analyse Abbott together

PenkeI guess you are interested in Abbott Laboratories. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Abbott Laboratories. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Abbott Laboratories

I send you an email if I find something interesting about Abbott Laboratories.

Quick analysis of Abbott (30 sec.)










What can you expect buying and holding a share of Abbott? (30 sec.)

How much money do you get?

How much money do you get?
$8.13
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
$22.20
Expected worth in 1 year
$27.31
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
$13.25
Return On Investment
12.5%

For what price can you sell your share?

Current Price per Share
$105.92
Expected price per share
$102.05 - $113.10
How sure are you?
50%

1. Valuation of Abbott (5 min.)




Live pricePrice per Share (EOD)

$105.92

Intrinsic Value Per Share

$15.99 - $41.89

Total Value Per Share

$38.19 - $64.09

2. Growth of Abbott (5 min.)




Is Abbott growing?

Current yearPrevious yearGrowGrow %
How rich?$38.8b$36.9b$1.9b5.0%

How much money is Abbott making?

Current yearPrevious yearGrowGrow %
Making money$5.7b$6.9b-$1.2b-21.1%
Net Profit Margin14.3%15.9%--

How much money comes from the company's main activities?

3. Financial Health of Abbott (5 min.)




4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  


Richest
#2 / 332

Most Revenue
#2 / 332

Most Profit
#1 / 332

What can you expect buying and holding a share of Abbott? (5 min.)

Welcome investor! Abbott's management wants to use your money to grow the business. In return you get a share of Abbott.

What can you expect buying and holding a share of Abbott?

First you should know what it really means to hold a share of Abbott. And how you can make/lose money.

Speculation

The Price per Share of Abbott is $105.92. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Abbott.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Abbott, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $22.20. Based on the TTM, the Book Value Change Per Share is $1.28 per quarter. Based on the YOY, the Book Value Change Per Share is $0.78 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $2.03 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Abbott.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps3.273.1%3.273.1%3.933.7%3.153.0%2.202.1%
Usd Book Value Change Per Share1.281.2%1.281.2%0.780.7%0.970.9%0.760.7%
Usd Dividend Per Share2.031.9%2.031.9%1.881.8%1.681.6%1.311.2%
Usd Total Gains Per Share3.313.1%3.313.1%2.662.5%2.652.5%2.072.0%
Usd Price Per Share110.07-110.07-109.79-111.39-81.47-
Price to Earnings Ratio33.64-33.64-27.93-36.53-54.57-
Price-to-Total Gains Ratio33.24-33.24-41.26-44.07-43.96-
Price to Book Ratio4.96-4.96-5.25-5.61-4.59-
Price-to-Total Gains Ratio33.24-33.24-41.26-44.07-43.96-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share105.92
Number of shares9
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share2.031.68
Usd Book Value Change Per Share1.280.97
Usd Total Gains Per Share3.312.65
Gains per Quarter (9 shares)29.8023.85
Gains per Year (9 shares)119.2195.39
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
17346109613585
21469222812170180
3220138347182105275
4293184466242139370
5366230585303174465
6439276704363209560
7512322823424244655
8586368942484279750
96594141061545314845
107324601180605349940

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%35.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%6.04.00.060.0%27.08.00.077.1%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%35.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%33.02.00.094.3%

Fundamentals of Abbott

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Fundamental data was last updated by Penke on 2024-05-02 08:54:07.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Abbott Laboratories.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Abbott earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Abbott to the Medical Devices industry mean.
  • A Net Profit Margin of 14.3% means that $0.14 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Abbott Laboratories:

  • The MRQ is 14.3%. The company is making a huge profit. +2
  • The TTM is 14.3%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ14.3%TTM14.3%0.0%
TTM14.3%YOY15.9%-1.6%
TTM14.3%5Y14.2%+0.0%
5Y14.2%10Y12.0%+2.2%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ14.3%-11.2%+25.5%
TTM14.3%-20.4%+34.7%
YOY15.9%-13.3%+29.2%
5Y14.2%-20.4%+34.6%
10Y12.0%-24.9%+36.9%
1.1.2. Return on Assets

Shows how efficient Abbott is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Abbott to the Medical Devices industry mean.
  • 7.8% Return on Assets means that Abbott generated $0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Abbott Laboratories:

  • The MRQ is 7.8%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 7.8%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ7.8%TTM7.8%0.0%
TTM7.8%YOY9.3%-1.5%
TTM7.8%5Y7.6%+0.2%
5Y7.6%10Y6.1%+1.5%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ7.8%-4.0%+11.8%
TTM7.8%-4.6%+12.4%
YOY9.3%-4.2%+13.5%
5Y7.6%-3.8%+11.4%
10Y6.1%-4.8%+10.9%
1.1.3. Return on Equity

Shows how efficient Abbott is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Abbott to the Medical Devices industry mean.
  • 14.8% Return on Equity means Abbott generated $0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Abbott Laboratories:

  • The MRQ is 14.8%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 14.8%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ14.8%TTM14.8%0.0%
TTM14.8%YOY18.9%-4.1%
TTM14.8%5Y15.8%-1.0%
5Y15.8%10Y12.7%+3.1%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ14.8%-4.1%+18.9%
TTM14.8%-5.6%+20.4%
YOY18.9%-5.3%+24.2%
5Y15.8%-6.1%+21.9%
10Y12.7%-6.7%+19.4%

1.2. Operating Efficiency of Abbott Laboratories.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Abbott is operating .

  • Measures how much profit Abbott makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Abbott to the Medical Devices industry mean.
  • An Operating Margin of 18.3% means the company generated $0.18  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Abbott Laboratories:

  • The MRQ is 18.3%. The company is operating efficient. +1
  • The TTM is 18.3%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ18.3%TTM18.3%0.0%
TTM18.3%YOY19.2%-0.9%
TTM18.3%5Y17.3%+1.0%
5Y17.3%10Y14.9%+2.5%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ18.3%-24.1%+42.4%
TTM18.3%-16.4%+34.7%
YOY19.2%-13.4%+32.6%
5Y17.3%-19.9%+37.2%
10Y14.9%-25.0%+39.9%
1.2.2. Operating Ratio

Measures how efficient Abbott is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 0.84 means that the operating costs are $0.84 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Abbott Laboratories:

  • The MRQ is 0.838. The company is less efficient in keeping operating costs low.
  • The TTM is 0.838. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.838TTM0.8380.000
TTM0.838YOY0.808+0.030
TTM0.8385Y0.831+0.008
5Y0.83110Y0.855-0.024
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8381.428-0.590
TTM0.8381.424-0.586
YOY0.8081.396-0.588
5Y0.8311.416-0.585
10Y0.8551.375-0.520

1.3. Liquidity of Abbott Laboratories.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Abbott is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 1.64 means the company has $1.64 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Abbott Laboratories:

  • The MRQ is 1.638. The company is able to pay all its short-term debts. +1
  • The TTM is 1.638. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.638TTM1.6380.000
TTM1.638YOY1.629+0.009
TTM1.6385Y1.655-0.017
5Y1.65510Y1.917-0.262
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6382.685-1.047
TTM1.6382.697-1.059
YOY1.6293.466-1.837
5Y1.6553.629-1.974
10Y1.9173.507-1.590
1.3.2. Quick Ratio

Measures if Abbott is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Abbott to the Medical Devices industry mean.
  • A Quick Ratio of 1.03 means the company can pay off $1.03 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Abbott Laboratories:

  • The MRQ is 1.028. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.028. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.028TTM1.0280.000
TTM1.028YOY1.249-0.221
TTM1.0285Y1.132-0.104
5Y1.13210Y1.370-0.238
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0281.521-0.493
TTM1.0281.666-0.638
YOY1.2492.142-0.893
5Y1.1322.316-1.184
10Y1.3702.416-1.046

1.4. Solvency of Abbott Laboratories.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Abbott assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Abbott to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.47 means that Abbott assets are financed with 47.0% credit (debt) and the remaining percentage (100% - 47.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Abbott Laboratories:

  • The MRQ is 0.470. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.470. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.470TTM0.4700.000
TTM0.470YOY0.504-0.035
TTM0.4705Y0.516-0.046
5Y0.51610Y0.528-0.012
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4700.402+0.068
TTM0.4700.390+0.080
YOY0.5040.343+0.161
5Y0.5160.442+0.074
10Y0.5280.460+0.068
1.4.2. Debt to Equity Ratio

Measures if Abbott is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Abbott to the Medical Devices industry mean.
  • A Debt to Equity ratio of 89.1% means that company has $0.89 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Abbott Laboratories:

  • The MRQ is 0.891. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.891. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.891TTM0.8910.000
TTM0.891YOY1.023-0.132
TTM0.8915Y1.078-0.187
5Y1.07810Y1.145-0.067
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8910.589+0.302
TTM0.8910.573+0.318
YOY1.0230.492+0.531
5Y1.0780.624+0.454
10Y1.1450.700+0.445

2. Market Valuation of Abbott Laboratories

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Abbott generates.

  • Above 15 is considered overpriced but always compare Abbott to the Medical Devices industry mean.
  • A PE ratio of 33.64 means the investor is paying $33.64 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Abbott Laboratories:

  • The EOD is 32.370. Based on the earnings, the company is overpriced. -1
  • The MRQ is 33.638. Based on the earnings, the company is overpriced. -1
  • The TTM is 33.638. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD32.370MRQ33.638-1.268
MRQ33.638TTM33.6380.000
TTM33.638YOY27.934+5.704
TTM33.6385Y36.528-2.890
5Y36.52810Y54.573-18.045
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD32.370-0.984+33.354
MRQ33.638-1.709+35.347
TTM33.638-2.190+35.828
YOY27.934-2.629+30.563
5Y36.528-2.300+38.828
10Y54.573-1.789+56.362
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Abbott Laboratories:

  • The EOD is 36.619. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 38.053. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 38.053. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD36.619MRQ38.053-1.435
MRQ38.053TTM38.0530.000
TTM38.053YOY24.817+13.237
TTM38.0535Y32.108+5.945
5Y32.10810Y31.321+0.787
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD36.619-0.986+37.605
MRQ38.053-1.578+39.631
TTM38.053-2.973+41.026
YOY24.817-6.238+31.055
5Y32.108-4.850+36.958
10Y31.321-5.292+36.613
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Abbott is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 4.96 means the investor is paying $4.96 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Abbott Laboratories:

  • The EOD is 4.771. Based on the equity, the company is fair priced.
  • The MRQ is 4.958. Based on the equity, the company is fair priced.
  • The TTM is 4.958. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.771MRQ4.958-0.187
MRQ4.958TTM4.9580.000
TTM4.958YOY5.248-0.290
TTM4.9585Y5.613-0.654
5Y5.61310Y4.592+1.020
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD4.7711.954+2.817
MRQ4.9582.376+2.582
TTM4.9582.468+2.490
YOY5.2483.169+2.079
5Y5.6133.906+1.707
10Y4.5924.273+0.319
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Abbott Laboratories.

3.1. Institutions holding Abbott Laboratories

Institutions are holding 76.824% of the shares of Abbott Laboratories.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc9.0160.37681564447006793590.4361
2023-12-31BlackRock Inc7.72620.3763134064516-2327088-1.7062
2023-12-31Capital Research Global Investors4.99022.34488658861475277789.5215
2023-12-31State Street Corporation4.30430.39997468717614539691.9854
2023-12-31Capital Research & Mgmt Co - Division 33.70541.58656429478414578472.32
2023-12-31Morgan Stanley - Brokerage Accounts2.07110.3486359368272964250.8317
2023-12-31Geode Capital Management, LLC1.89340.3772328534004299811.3261
2023-12-31Wellington Management Company LLP1.85780.66153223610110273903.292
2023-12-31Goldman Sachs Group Inc1.31510.22542281888014023272159.4349
2023-12-31Northern Trust Corp1.24650.430921628826-1387409-6.028
2023-12-31NORGES BANK1.10780.369719222637197411511.4451
2023-12-31Wells Fargo & Co0.94920.472916470904-118216-0.7126
2023-12-31Bank of America Corp0.94520.1819164016611255640.7715
2023-12-31Bank of New York Mellon Corp0.87130.3374151189285159253.533
2023-12-31Legal & General Group PLC0.82410.403914299250187341115.0767
2023-12-31State Farm Mutual Automobile Ins Co0.7831.43831358711800
2023-12-31Polen Capital0.77733.57851348684861120.0453
2023-12-31JPMorgan Chase & Co0.76520.140413277595-3457426-20.6598
2023-12-31HHG PLC0.76360.869913249744381166140.386
2023-12-31Nuveen Asset Management, LLC0.71270.4376123661422862582.3697
Total 46.625415.3584809034651+28198928+3.5%

3.2. Funds holding Abbott Laboratories

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Performer (AFRIS)5.02760.103587238583872385830
2024-02-29Vanguard Total Stock Mkt Idx Inv3.13860.416754459809-116750-0.2139
2024-03-31Vanguard Institutional 500 Index Trust2.52170.4473437559814280830.988
2023-12-31Capital Group Investment Co of Amer Comp1.54192.329826754374412439518.2254
2024-03-31American Funds Invmt Co of Amer A1.35442.023323501646-3252728-12.1577
2023-12-31Capital Group American Mutual Comp1.22682.5537212867535159222.4839
2024-03-31American Funds American Mutual A1.2252.593421255720-31033-0.1458
2024-03-31SPDR® S&P 500 ETF Trust1.20620.446120930410-162898-0.7723
2024-02-29Fidelity 500 Index1.19950.4793208129232094301.0165
2024-03-28iShares Core S&P 500 ETF1.03720.4466179967601323520.7409
2023-12-31Capital Group World Growth & Inc Cmp0.92171.4974159925997964845.2414
2024-03-31American Funds Capital World Gr&Inc A0.92061.516315973641-18958-0.1185
2024-03-31Vanguard Value Index Inv0.83070.961414414958-81529-0.5624
2024-03-31American Funds Capital Income Bldr A0.791.53451370720510695008.4628
2024-03-31Health Care Select Sector SPDR® ETF0.75073.603413025358-65632-0.5014
2023-12-31Capital Group AMCAP Composite0.74991.782613011963302680.2332
2024-03-31VA CollegeAmerica Amcap 529A0.74891.768312994988-16975-0.1305
2024-03-31American Funds Growth Fund of Amer A0.74570.5565129391142409531.8975
2023-12-31Capital Group Growth Fnd of Amer Comp0.73180.56131269816100
2023-12-31Vanguard Dividend Growth Inv0.67362.455211689056127260112.2172
Total 27.342528.0766474440002+92312068+19.5%

3.3. Insider Transactions

Insiders are holding 0.539% of the shares of Abbott Laboratories.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-01John A Jr. MccoySELL472118.5
2024-03-01Daniel Gesua Sive SalvadoriSELL963118.5
2024-02-23Andrea F WainerSELL12500120
2024-01-29Andrea F WainerSELL42500112.5
2023-12-14Andrea F WainerSELL15000108
2023-10-26Daniel J StarksSELL5000094.05
2023-08-08Andrea F WainerSELL10400105.03
2023-07-27Daniel J StarksSELL50000113.76
2023-05-02Andrea F WainerSELL8226110.56
2023-05-02Daniel J StarksSELL50000111.02

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Abbott Laboratories compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.2781.2780%0.785+63%0.968+32%0.764+67%
Book Value Per Share--22.20022.2000%20.921+6%19.862+12%17.115+30%
Current Ratio--1.6381.6380%1.629+1%1.655-1%1.917-15%
Debt To Asset Ratio--0.4700.4700%0.504-7%0.516-9%0.528-11%
Debt To Equity Ratio--0.8910.8910%1.023-13%1.078-17%1.145-22%
Dividend Per Share--2.0332.0330%1.876+8%1.681+21%1.307+56%
Eps--3.2723.2720%3.930-17%3.148+4%2.202+49%
Free Cash Flow Per Share--2.8932.8930%4.424-35%3.576-19%2.696+7%
Free Cash Flow To Equity Per Share---1.162-1.1620%0.095-1320%0.493-336%0.620-287%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--41.888--------
Intrinsic Value_10Y_min--15.990--------
Intrinsic Value_1Y_max--4.091--------
Intrinsic Value_1Y_min--2.445--------
Intrinsic Value_3Y_max--12.373--------
Intrinsic Value_3Y_min--6.659--------
Intrinsic Value_5Y_max--20.753--------
Intrinsic Value_5Y_min--10.090--------
Market Cap183790268989.440-5%192512430000.000192512430000.0000%193669560000.000-1%197642530000.000-3%143874518530.688+34%
Net Profit Margin--0.1430.1430%0.159-10%0.142+0%0.120+19%
Operating Margin--0.1830.1830%0.192-4%0.173+6%0.149+23%
Operating Ratio--0.8380.8380%0.808+4%0.831+1%0.855-2%
Pb Ratio4.771-4%4.9584.9580%5.248-6%5.613-12%4.592+8%
Pe Ratio32.370-4%33.63833.6380%27.934+20%36.528-8%54.573-38%
Price Per Share105.920-4%110.070110.0700%109.790+0%111.390-1%81.469+35%
Price To Free Cash Flow Ratio36.619-4%38.05338.0530%24.817+53%32.108+19%31.321+21%
Price To Total Gains Ratio31.985-4%33.23933.2390%41.264-19%44.075-25%43.964-24%
Quick Ratio--1.0281.0280%1.249-18%1.132-9%1.370-25%
Return On Assets--0.0780.0780%0.093-16%0.076+2%0.061+28%
Return On Equity--0.1480.1480%0.189-22%0.158-6%0.127+17%
Total Gains Per Share--3.3123.3120%2.661+24%2.650+25%2.071+60%
Usd Book Value--38827000000.00038827000000.0000%36905000000.000+5%35212000000.000+10%30156200000.000+29%
Usd Book Value Change Per Share--1.2781.2780%0.785+63%0.968+32%0.764+67%
Usd Book Value Per Share--22.20022.2000%20.921+6%19.862+12%17.115+30%
Usd Dividend Per Share--2.0332.0330%1.876+8%1.681+21%1.307+56%
Usd Eps--3.2723.2720%3.930-17%3.148+4%2.202+49%
Usd Free Cash Flow--5059000000.0005059000000.0000%7804000000.000-35%6346600000.000-20%4761000000.000+6%
Usd Free Cash Flow Per Share--2.8932.8930%4.424-35%3.576-19%2.696+7%
Usd Free Cash Flow To Equity Per Share---1.162-1.1620%0.095-1320%0.493-336%0.620-287%
Usd Market Cap183790268989.440-5%192512430000.000192512430000.0000%193669560000.000-1%197642530000.000-3%143874518530.688+34%
Usd Price Per Share105.920-4%110.070110.0700%109.790+0%111.390-1%81.469+35%
Usd Profit--5723000000.0005723000000.0000%6933000000.000-17%5581800000.000+3%3886100000.000+47%
Usd Revenue--40109000000.00040109000000.0000%43653000000.000-8%38669800000.000+4%31282200000.000+28%
Usd Total Gains Per Share--3.3123.3120%2.661+24%2.650+25%2.071+60%
 EOD+4 -4MRQTTM+0 -0YOY+14 -215Y+21 -1410Y+27 -8

4.2. Fundamental Score

Let's check the fundamental score of Abbott Laboratories based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1532.370
Price to Book Ratio (EOD)Between0-14.771
Net Profit Margin (MRQ)Greater than00.143
Operating Margin (MRQ)Greater than00.183
Quick Ratio (MRQ)Greater than11.028
Current Ratio (MRQ)Greater than11.638
Debt to Asset Ratio (MRQ)Less than10.470
Debt to Equity Ratio (MRQ)Less than10.891
Return on Equity (MRQ)Greater than0.150.148
Return on Assets (MRQ)Greater than0.050.078
Total7/10 (70.0%)

4.3. Technical Score

Let's check the technical score of Abbott Laboratories based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.335
Ma 20Greater thanMa 50108.192
Ma 50Greater thanMa 100112.925
Ma 100Greater thanMa 200112.236
OpenGreater thanClose106.660
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Total Other Income Expense Net -455,00066,000-389,000175,000-214,000158,000-56,000494,000438,000



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets73,214,000
Total Liabilities34,387,000
Total Stockholder Equity38,603,000
 As reported
Total Liabilities 34,387,000
Total Stockholder Equity+ 38,603,000
Total Assets = 73,214,000

Assets

Total Assets73,214,000
Total Current Assets22,670,000
Long-term Assets50,544,000
Total Current Assets
Cash And Cash Equivalents 6,896,000
Short-term Investments 383,000
Net Receivables 6,565,000
Inventory 6,570,000
Other Current Assets 2,256,000
Total Current Assets  (as reported)22,670,000
Total Current Assets  (calculated)22,670,000
+/-0
Long-term Assets
Property Plant Equipment 11,276,000
Goodwill 23,679,000
Long Term Investments 799,000
Intangible Assets 8,815,000
Long-term Assets Other 5,975,000
Long-term Assets  (as reported)50,544,000
Long-term Assets  (calculated)50,544,000
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities13,841,000
Long-term Liabilities20,546,000
Total Stockholder Equity38,603,000
Total Current Liabilities
Short-term Debt 1,325,000
Short Long Term Debt 1,080,000
Accounts payable 4,295,000
Other Current Liabilities 7,729,000
Total Current Liabilities  (as reported)13,841,000
Total Current Liabilities  (calculated)14,429,000
+/- 588,000
Long-term Liabilities
Long term Debt 13,599,000
Capital Lease Obligations 949,000
Long-term Liabilities Other 3,466,000
Long-term Liabilities  (as reported)20,546,000
Long-term Liabilities  (calculated)18,014,000
+/- 2,532,000
Total Stockholder Equity
Common Stock24,869,000
Retained Earnings 37,554,000
Accumulated Other Comprehensive Income -7,839,000
Other Stockholders Equity -15,981,000
Total Stockholder Equity (as reported)38,603,000
Total Stockholder Equity (calculated)38,603,000
+/-0
Other
Capital Stock24,869,000
Cash and Short Term Investments 7,279,000
Common Stock Shares Outstanding 1,749,000
Current Deferred Revenue492,000
Liabilities and Stockholders Equity 73,214,000
Net Debt 8,977,000
Net Invested Capital 53,282,000
Net Working Capital 8,829,000
Property Plant and Equipment Gross 21,933,000
Short Long Term Debt Total 15,873,000



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-311998-12-311997-12-311996-12-311995-12-311994-12-311993-12-311992-12-311991-12-311990-12-311989-12-311988-12-311987-12-311986-12-311985-12-31
> Total Assets 
3,468,400
3,865,600
4,385,700
4,825,100
4,851,600
5,563,200
6,255,300
6,941,200
7,688,569
8,523,724
9,412,580
11,125,600
12,061,068
13,216,213
14,471,044
15,283,254
23,296,423
24,259,102
26,715,342
28,767,494
29,141,203
36,178,172
39,713,924
42,419,204
52,416,623
59,462,266
60,276,893
67,234,944
42,953,000
41,275,000
41,247,000
52,666,000
76,250,000
67,173,000
67,887,000
72,548,000
75,196,000
74,438,000
73,214,000
73,214,00074,438,00075,196,00072,548,00067,887,00067,173,00076,250,00052,666,00041,247,00041,275,00042,953,00067,234,94460,276,89359,462,26652,416,62342,419,20439,713,92436,178,17229,141,20328,767,49426,715,34224,259,10223,296,42315,283,25414,471,04413,216,21312,061,06811,125,6009,412,5808,523,7247,688,5696,941,2006,255,3005,563,2004,851,6004,825,1004,385,7003,865,6003,468,400
   > Total Current Assets 
1,680,400
1,888,900
2,155,500
2,353,000
2,102,800
2,461,200
2,891,100
3,231,700
3,585,535
3,876,328
4,226,711
4,480,902
5,038,208
5,553,136
6,419,754
7,376,241
8,419,189
9,121,772
10,290,415
10,734,485
11,386,028
11,281,883
14,042,733
17,042,559
23,313,891
22,317,529
23,768,774
31,322,583
19,247,000
15,261,000
14,155,000
26,776,000
20,147,000
14,632,000
15,667,000
20,441,000
24,239,000
25,224,000
22,670,000
22,670,00025,224,00024,239,00020,441,00015,667,00014,632,00020,147,00026,776,00014,155,00015,261,00019,247,00031,322,58323,768,77422,317,52923,313,89117,042,55914,042,73311,281,88311,386,02810,734,48510,290,4159,121,7728,419,1897,376,2416,419,7545,553,1365,038,2084,480,9024,226,7113,876,3283,585,5353,231,7002,891,1002,461,2002,102,8002,353,0002,155,5001,888,9001,680,400
       Cash And Cash Equivalents 
437,500
481,600
519,900
582,600
13,600
34,000
60,400
116,600
300,676
290,272
281,197
110,209
230,024
308,230
608,097
914,218
657,378
704,450
995,124
1,225,628
2,893,687
521,192
2,456,384
4,112,022
8,809,339
3,648,371
6,812,820
10,802,163
3,475,000
4,063,000
5,001,000
18,620,000
9,407,000
3,844,000
3,860,000
6,838,000
9,799,000
9,882,000
6,896,000
6,896,0009,882,0009,799,0006,838,0003,860,0003,844,0009,407,00018,620,0005,001,0004,063,0003,475,00010,802,1636,812,8203,648,3718,809,3394,112,0222,456,384521,1922,893,6871,225,628995,124704,450657,378914,218608,097308,230230,024110,209281,197290,272300,676116,60060,40034,00013,600582,600519,900481,600437,500
       Short-term Investments 
0
0
0
0
0
0
0
0
78,149
25,056
34,500
12,875
28,986
75,087
115,199
242,500
56,162
261,677
291,297
833,334
62,406
852,243
364,443
967,603
1,122,709
1,803,079
1,284,539
4,371,821
4,623,000
397,000
1,124,000
155,000
203,000
242,000
280,000
310,000
450,000
288,000
383,000
383,000288,000450,000310,000280,000242,000203,000155,0001,124,000397,0004,623,0004,371,8211,284,5391,803,0791,122,709967,603364,443852,24362,406833,334291,297261,67756,162242,500115,19975,08728,98612,87534,50025,05678,14900000000
       Net Receivables 
563,300
624,900
728,000
781,800
892,700
1,070,200
1,150,900
1,244,400
1,336,222
1,468,519
1,563,038
1,708,807
1,782,326
1,950,058
2,055,839
2,179,451
2,812,727
2,927,370
3,313,377
3,696,115
3,576,794
4,231,142
4,946,876
5,465,660
6,541,941
7,184,034
7,683,920
7,612,860
3,986,000
3,586,000
3,418,000
3,248,000
5,249,000
5,182,000
5,425,000
6,414,000
6,487,000
8,881,000
6,565,000
6,565,0008,881,0006,487,0006,414,0005,425,0005,182,0005,249,0003,248,0003,418,0003,586,0003,986,0007,612,8607,683,9207,184,0346,541,9415,465,6604,946,8764,231,1423,576,7943,696,1153,313,3772,927,3702,812,7272,179,4512,055,8391,950,0581,782,3261,708,8071,563,0381,468,5191,336,2221,244,4001,150,9001,070,200892,700781,800728,000624,900563,300
       Inventory 
463,800
524,400
612,200
611,300
696,000
777,600
815,400
863,800
940,533
1,018,191
1,110,941
1,238,205
1,279,900
1,410,609
1,495,444
1,741,331
2,212,035
2,441,302
2,738,439
2,620,463
2,541,979
2,806,421
2,951,442
2,775,849
3,264,877
3,188,734
3,284,249
3,792,313
2,693,000
2,643,000
2,599,000
2,434,000
3,601,000
3,796,000
4,316,000
5,012,000
5,157,000
6,173,000
6,570,000
6,570,0006,173,0005,157,0005,012,0004,316,0003,796,0003,601,0002,434,0002,599,0002,643,0002,693,0003,792,3133,284,2493,188,7343,264,8772,775,8492,951,4422,806,4212,541,9792,620,4632,738,4392,441,3022,212,0351,741,3311,495,4441,410,6091,279,9001,238,2051,110,9411,018,191940,533863,800815,400777,600696,000611,300612,200524,400463,800
       Other Current Assets 
215,800
258,000
295,400
377,300
500,500
579,400
864,400
1,006,900
458,026
549,091
1,237,035
1,410,806
1,716,972
1,809,152
2,145,175
2,298,741
2,680,887
2,786,973
2,952,178
247,056
129,902
2,870,885
3,323,588
1,258,554
3,575,025
6,493,311
4,703,246
4,743,426
4,470,000
4,572,000
2,013,000
2,319,000
1,687,000
1,568,000
1,786,000
1,867,000
2,346,000
2,663,000
2,256,000
2,256,0002,663,0002,346,0001,867,0001,786,0001,568,0001,687,0002,319,0002,013,0004,572,0004,470,0004,743,4264,703,2466,493,3113,575,0251,258,5543,323,5882,870,885129,902247,0562,952,1782,786,9732,680,8872,298,7412,145,1751,809,1521,716,9721,410,8061,237,035549,091458,0261,006,900864,400579,400500,500377,300295,400258,000215,800
   > Long-term Assets 
1,788,000
1,976,700
2,230,200
2,472,100
2,748,800
3,102,000
3,364,200
3,709,500
4,103,034
4,647,396
5,185,869
6,644,698
7,022,860
7,663,077
8,051,290
7,907,013
14,877,234
15,137,330
16,424,927
18,033,009
17,755,175
24,896,289
25,671,191
25,376,645
29,102,732
37,144,737
36,508,119
35,912,361
23,706,000
26,014,000
27,092,000
25,890,000
56,103,000
52,541,000
52,220,000
52,107,000
50,957,000
49,214,000
50,544,000
50,544,00049,214,00050,957,00052,107,00052,220,00052,541,00056,103,00025,890,00027,092,00026,014,00023,706,00035,912,36136,508,11937,144,73729,102,73225,376,64525,671,19124,896,28917,755,17518,033,00916,424,92715,137,33014,877,2347,907,0138,051,2907,663,0777,022,8606,644,6985,185,8694,647,3964,103,0343,709,5003,364,2003,102,0002,748,8002,472,1002,230,2001,976,7001,788,000
       Property Plant Equipment 
1,368,500
1,543,300
1,741,600
1,952,600
2,090,200
2,375,800
2,662,100
3,099,200
3,510,991
3,920,850
4,249,538
4,461,543
4,569,691
4,738,843
4,770,059
4,816,911
5,551,547
5,828,122
6,281,806
6,007,874
6,003,141
6,946,435
7,518,149
7,219,166
7,619,489
7,970,956
7,873,955
8,063,047
5,905,000
5,935,000
5,730,000
5,705,000
7,607,000
7,563,000
8,038,000
9,029,000
8,959,000
9,162,000
11,276,000
11,276,0009,162,0008,959,0009,029,0008,038,0007,563,0007,607,0005,705,0005,730,0005,935,0005,905,0008,063,0477,873,9557,970,9567,619,4897,219,1667,518,1496,946,4356,003,1416,007,8746,281,8065,828,1225,551,5474,816,9114,770,0594,738,8434,569,6914,461,5434,249,5383,920,8503,510,9913,099,2002,662,1002,375,8002,090,2001,952,6001,741,6001,543,3001,368,500
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,732,533
4,449,408
5,685,124
5,219,247
9,449,281
10,128,841
9,987,361
13,200,174
15,930,077
15,705,380
15,774,127
9,772,000
10,067,000
9,638,000
7,683,000
24,020,000
23,254,000
23,195,000
23,744,000
23,231,000
22,799,000
23,679,000
23,679,00022,799,00023,231,00023,744,00023,195,00023,254,00024,020,0007,683,0009,638,00010,067,0009,772,00015,774,12715,705,38015,930,07713,200,1749,987,36110,128,8419,449,2815,219,2475,685,1244,449,4083,732,53300000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,132,866
302,049
378,225
273,595
119,000
229,000
4,041,000
2,947,000
883,000
897,000
883,000
821,000
816,000
766,000
799,000
799,000766,000816,000821,000883,000897,000883,0002,947,0004,041,000229,000119,000273,595378,225302,0491,132,866000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
979,793
1,112,126
1,349,822
1,574,851
1,555,260
7,294,320
7,651,781
8,539,290
10,856,718
9,960,894
6,403,619
5,720,478
5,151,106
6,291,989
12,151,628
9,989,636
8,588,285
5,735,000
6,198,000
5,562,000
4,539,000
21,473,000
18,942,000
17,025,000
14,784,000
12,739,000
10,454,000
8,815,000
8,815,00010,454,00012,739,00014,784,00017,025,00018,942,00021,473,0004,539,0005,562,0006,198,0005,735,0008,588,2859,989,63612,151,6286,291,9895,151,1065,720,4786,403,6199,960,89410,856,7188,539,2907,651,7817,294,3201,555,2601,574,8511,349,8221,112,126979,79300000000000
       Long-term Assets Other 
419,500
433,400
488,600
519,500
658,600
726,200
702,100
610,300
592,043
726,546
936,331
1,203,362
1,341,043
1,574,412
1,706,380
1,534,842
647,214
-20,869
329,357
140,488
1,791,140
1,229,873
1,125,262
0
858,214
790,027
2,560,923
3,213,307
66,000
1,934,000
2,000
2,753,000
176,000
17,000
52,220,000
3,729,000
5,212,000
6,033,000
5,975,000
5,975,0006,033,0005,212,0003,729,00052,220,00017,000176,0002,753,0002,0001,934,00066,0003,213,3072,560,923790,027858,21401,125,2621,229,8731,791,140140,488329,357-20,869647,2141,534,8421,706,3801,574,4121,341,0431,203,362936,331726,546592,043610,300702,100726,200658,600519,500488,600433,400419,500
> Total Liabilities 
1,597,700
2,086,700
2,292,200
2,360,500
2,125,200
2,729,600
3,052,300
3,593,600
4,013,640
4,474,324
5,015,733
6,305,418
7,062,391
7,502,552
7,043,449
6,712,348
14,236,991
13,594,549
13,643,084
14,441,711
14,725,932
22,123,986
21,935,384
24,939,653
29,517,894
36,985,802
35,750,748
40,421,712
17,686,000
19,636,000
19,921,000
31,949,000
45,152,000
36,451,000
36,586,000
39,545,000
39,172,000
37,533,000
34,387,000
34,387,00037,533,00039,172,00039,545,00036,586,00036,451,00045,152,00031,949,00019,921,00019,636,00017,686,00040,421,71235,750,74836,985,80229,517,89424,939,65321,935,38422,123,98614,725,93214,441,71113,643,08413,594,54914,236,9916,712,3487,043,4497,502,5527,062,3916,305,4185,015,7334,474,3244,013,6403,593,6003,052,3002,729,6002,125,2002,360,5002,292,2002,086,7001,597,700
   > Total Current Liabilities 
788,500
1,303,500
1,486,800
1,439,700
1,383,600
2,001,100
2,229,300
2,782,500
3,094,933
3,475,866
3,790,314
4,343,717
5,034,468
4,962,126
4,516,711
4,297,540
7,926,817
7,002,202
7,639,535
6,825,644
7,415,514
11,951,195
9,103,278
11,591,908
13,049,489
17,262,434
15,480,228
13,280,176
9,507,000
10,532,000
9,186,000
6,660,000
8,912,000
9,012,000
10,863,000
11,907,000
13,105,000
15,489,000
13,841,000
13,841,00015,489,00013,105,00011,907,00010,863,0009,012,0008,912,0006,660,0009,186,00010,532,0009,507,00013,280,17615,480,22817,262,43413,049,48911,591,9089,103,27811,951,1957,415,5146,825,6447,639,5357,002,2027,926,8174,297,5404,516,7114,962,1265,034,4684,343,7173,790,3143,475,8663,094,9332,782,5002,229,3002,001,1001,383,6001,439,7001,486,8001,303,500788,500
       Short-term Debt 
122,900
591,700
606,400
493,300
300,500
663,800
544,300
916,300
843,594
772,503
1,049,863
1,383,727
1,781,352
1,759,076
896,271
479,454
2,953,335
2,148,654
2,537,357
1,992,683
2,062,010
5,401,261
2,725,915
2,731,975
5,189,620
6,394,766
3,374,755
2,390,662
3,173,000
4,437,000
3,130,000
1,325,000
714,000
207,000
1,478,000
220,000
754,000
2,251,000
1,325,000
1,325,0002,251,000754,000220,0001,478,000207,000714,0001,325,0003,130,0004,437,0003,173,0002,390,6623,374,7556,394,7665,189,6202,731,9752,725,9155,401,2612,062,0101,992,6832,537,3572,148,6542,953,335479,454896,2711,759,0761,781,3521,383,7271,049,863772,503843,594916,300544,300663,800300,500493,300606,400591,700122,900
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500,000
442,000
1,325,000
714,000
207,000
1,478,000
220,000
754,000
2,251,000
1,080,000
1,080,0002,251,000754,000220,0001,478,000207,000714,0001,325,000442,000500,00000000000000000000000000000000
       Accounts payable 
0
0
0
0
309,800
351,200
522,400
597,200
638,509
671,100
755,921
923,018
1,001,058
1,056,641
1,226,854
1,355,985
1,525,215
1,661,650
1,754,367
1,054,464
1,032,516
1,175,590
1,219,529
1,351,436
1,280,542
1,535,759
1,721,127
1,796,990
1,026,000
1,064,000
1,081,000
1,178,000
2,402,000
2,975,000
3,252,000
3,946,000
4,408,000
4,607,000
4,295,000
4,295,0004,607,0004,408,0003,946,0003,252,0002,975,0002,402,0001,178,0001,081,0001,064,0001,026,0001,796,9901,721,1271,535,7591,280,5421,351,4361,219,5291,175,5901,032,5161,054,4641,754,3671,661,6501,525,2151,355,9851,226,8541,056,6411,001,058923,018755,921671,100638,509597,200522,400351,200309,8000000
       Other Current Liabilities 
665,600
711,800
880,400
946,400
773,300
986,100
1,162,600
1,269,000
679,781
892,109
767,514
830,420
845,926
767,702
960,162
912,856
1,162,623
989,421
1,167,713
1,286,541
1,598,303
1,523,621
1,444,730
915,982
6,137,187
8,024,186
9,869,399
8,437,100
5,133,000
4,761,000
4,545,000
3,969,000
5,487,000
5,525,000
6,133,000
7,741,000
7,943,000
8,631,000
7,729,000
7,729,0008,631,0007,943,0007,741,0006,133,0005,525,0005,487,0003,969,0004,545,0004,761,0005,133,0008,437,1009,869,3998,024,1866,137,187915,9821,444,7301,523,6211,598,3031,286,5411,167,713989,4211,162,623912,856960,162767,702845,926830,420767,514892,109679,7811,269,0001,162,600986,100773,300946,400880,400711,800665,600
   > Long-term Liabilities 
809,200
783,200
805,400
920,800
741,600
728,500
823,000
811,100
918,707
998,458
1,225,419
1,961,701
2,027,923
2,540,426
2,526,738
2,414,808
6,310,174
6,592,347
6,003,549
7,616,067
7,310,418
10,172,791
12,832,106
13,347,745
16,468,405
19,723,368
20,270,520
27,141,536
8,179,000
9,104,000
10,735,000
25,289,000
36,240,000
27,439,000
25,723,000
27,638,000
26,067,000
22,044,000
20,546,000
20,546,00022,044,00026,067,00027,638,00025,723,00027,439,00036,240,00025,289,00010,735,0009,104,0008,179,00027,141,53620,270,52019,723,36816,468,40513,347,74512,832,10610,172,7917,310,4187,616,0676,003,5496,592,3476,310,1742,414,8082,526,7382,540,4262,027,9231,961,7011,225,419998,458918,707811,100823,000728,500741,600920,800805,400783,200809,200
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,266,294
12,523,517
12,039,822
18,085,302
3,388,000
3,408,000
5,871,000
20,681,000
27,210,000
19,359,000
16,661,000
18,527,000
17,296,000
14,522,000
0
014,522,00017,296,00018,527,00016,661,00019,359,00027,210,00020,681,0005,871,0003,408,0003,388,00018,085,30212,039,82212,523,51711,266,294000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,338,440
1,974,681
2,318,374
2,551,220
2,828,133
2,155,837
3,163,127
3,344,317
4,634,418
5,202,111
7,199,851
8,230,698
8,346,234
4,325,000
4,836,000
4,864,000
4,608,000
9,030,000
8,080,000
8,307,000
8,209,000
7,815,000
6,579,000
0
06,579,0007,815,0008,209,0008,307,0008,080,0009,030,0004,608,0004,864,0004,836,0004,325,0008,346,2348,230,6987,199,8515,202,1114,634,4183,344,3173,163,1272,155,8372,828,1332,551,2202,318,3741,974,6811,338,440000000000000000
> Total Stockholder Equity
1,870,700
1,778,900
2,093,500
2,464,600
2,726,400
2,833,600
3,203,000
3,347,600
3,674,929
4,049,400
4,396,847
4,820,182
4,998,677
5,713,661
7,427,595
8,570,906
9,059,432
10,664,553
13,072,258
14,325,783
14,415,271
14,054,186
17,778,540
17,479,551
22,855,627
22,388,135
24,439,833
26,720,961
25,171,000
21,526,000
21,211,000
20,538,000
30,897,000
30,524,000
31,088,000
32,784,000
35,802,000
36,686,000
38,603,000
38,603,00036,686,00035,802,00032,784,00031,088,00030,524,00030,897,00020,538,00021,211,00021,526,00025,171,00026,720,96124,439,83322,388,13522,855,62717,479,55117,778,54014,054,18614,415,27114,325,78313,072,25810,664,5539,059,4328,570,9067,427,5955,713,6614,998,6774,820,1824,396,8474,049,4003,674,9293,347,6003,203,0002,833,6002,726,4002,464,6002,093,5001,778,9001,870,700
   Common Stock
0
0
0
0
0
0
0
0
469,828
505,170
581,562
694,380
907,106
1,231,079
1,939,673
2,218,234
2,643,443
2,891,266
3,034,054
3,239,575
3,523,766
39,500
39,500
7,444,411
8,257,873,000
8,744,703,000
9,817,134,000
11,754,552
12,048,000
12,383,000
12,734,000
13,027,000
23,206,000
23,512,000
23,853,000
24,145,000
24,470,000
24,709,000
24,869,000
24,869,00024,709,00024,470,00024,145,00023,853,00023,512,00023,206,00013,027,00012,734,00012,383,00012,048,00011,754,5529,817,134,0008,744,703,0008,257,873,0007,444,41139,50039,5003,523,7663,239,5753,034,0542,891,2662,643,4432,218,2341,939,6731,231,079907,106694,380581,562505,170469,82800000000
   Retained Earnings 
1,844,200
1,702,500
1,926,800
2,266,000
2,532,800
2,528,000
2,867,900
2,990,700
3,364,952
3,652,434
3,926,917
4,262,804
4,427,997
4,554,648
6,174,007
7,229,586
7,281,395
8,601,386
9,691,484
10,033,440
10,404,568
9,568,728
10,805,809
13,825,383
17,054,027
18,927,101
20,907,362
24,150,996
21,979,000
22,874,000
25,757,000
25,565,000
23,978,000
24,560,000
25,847,000
27,627,000
31,528,000
35,257,000
37,554,000
37,554,00035,257,00031,528,00027,627,00025,847,00024,560,00023,978,00025,565,00025,757,00022,874,00021,979,00024,150,99620,907,36218,927,10117,054,02713,825,38310,805,8099,568,72810,404,56810,033,4409,691,4848,601,3867,281,3957,229,5866,174,0074,554,6484,427,9974,262,8043,926,9173,652,4343,364,9522,990,7002,867,9002,528,0002,532,8002,266,0001,926,8001,702,5001,844,200
   Accumulated Other Comprehensive Income 
-707,100
-881,800
-1,118,000
-1,337,100
-1,536,600
-1,881,800
-2,123,100
-2,397,900
-108,068
-56,659
-60,364
-86,397
-288,188
-25,331
-428,329
-621,328
-612,968
-596,254
576,416
1,273,622
699,192
389,766
2,081,763
-1,163,839
854,074
-1,366,846
-2,597,185
-3,593,678
-2,012,000
-5,053,000
-6,658,000
-7,263,000
-6,062,000
-7,586,000
-8,465,000
-8,946,000
-8,374,000
-8,051,000
-7,839,000
-7,839,000-8,051,000-8,374,000-8,946,000-8,465,000-7,586,000-6,062,000-7,263,000-6,658,000-5,053,000-2,012,000-3,593,678-2,597,185-1,366,846854,074-1,163,8392,081,763389,766699,1921,273,622576,416-596,254-612,968-621,328-428,329-25,331-288,188-86,397-60,364-56,659-108,068-2,397,900-2,123,100-1,881,800-1,536,600-1,337,100-1,118,000-881,800-707,100
   Capital Surplus 000000000000000000000000000000000000000
   Treasury Stock00-11,822,000-10,042,000-10,147,000-9,962,000-10,225,000-10,791,000-10,622,000-8,678,000-6,844,000-5,590,909-3,687,478-3,916,823-3,310,347-2,626,404-1,213,134-195,237-212,255-220,854-229,696-231,845-252,438-255,586000000000000000
   Other Stockholders Equity 
733,600
958,200
1,284,700
1,535,700
1,730,200
2,187,400
2,458,200
2,754,800
-51,783
-51,545
-51,268
-50,605
-48,238
-46,735
-257,756
-255,586
-252,438
-231,845
-229,696
-220,854
-212,255
4,056,192
4,851,468
-2,626,404
-8,252,925,474
-8,739,875,120
-9,811,004,344
-5,590,909
-6,844,000
-8,678,000
-10,622,000
-10,791,000
-10,225,000
-9,962,000
-10,147,000
-10,042,000
-11,822,000
-15,229,000
-15,981,000
-15,981,000-15,229,000-11,822,000-10,042,000-10,147,000-9,962,000-10,225,000-10,791,000-10,622,000-8,678,000-6,844,000-5,590,909-9,811,004,344-8,739,875,120-8,252,925,474-2,626,4044,851,4684,056,192-212,255-220,854-229,696-231,845-252,438-255,586-257,756-46,735-48,238-50,605-51,268-51,545-51,7832,754,8002,458,2002,187,4001,730,2001,535,7001,284,700958,200733,600



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue40,109,000
Cost of Revenue-17,975,000
Gross Profit22,134,00022,134,000
 
Operating Income (+$)
Gross Profit22,134,000
Operating Expense-15,656,000
Operating Income6,478,0006,478,000
 
Operating Expense (+$)
Research Development2,741,000
Selling General Administrative11,198,000
Selling And Marketing Expenses0
Operating Expense15,656,00013,939,000
 
Net Interest Income (+$)
Interest Income384,000
Interest Expense-637,000
Other Finance Cost-5,000
Net Interest Income-248,000
 
Pretax Income (+$)
Operating Income6,478,000
Net Interest Income-248,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)6,664,0006,040,000
EBIT - interestExpense = 6,705,000
6,664,000
6,360,000
Interest Expense637,000
Earnings Before Interest and Taxes (EBIT)7,342,0007,301,000
Earnings Before Interest and Taxes (EBITDA)10,585,000
 
After tax Income (+$)
Income Before Tax6,664,000
Tax Provision-1,027,000
Net Income From Continuing Ops5,162,0005,637,000
Net Income5,723,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses33,631,000
Total Other Income/Expenses Net438,000248,000
 

Technical Analysis of Abbott
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Abbott. The general trend of Abbott is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Abbott's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Abbott Laboratories.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 109.47 < 111.89 < 113.10.

The bearish price targets are: 104.50 > 104.25 > 102.05.

Tweet this
Abbott Laboratories Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Abbott Laboratories. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Abbott Laboratories Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Abbott Laboratories. The current macd is -1.72160871.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Abbott price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Abbott. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Abbott price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Abbott Laboratories Daily Moving Average Convergence/Divergence (MACD) ChartAbbott Laboratories Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Abbott Laboratories. The current adx is 35.08.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Abbott shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Abbott Laboratories Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Abbott Laboratories. The current sar is 108.29.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Abbott Laboratories Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Abbott Laboratories. The current rsi is 36.33. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Abbott Laboratories Daily Relative Strength Index (RSI) ChartAbbott Laboratories Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Abbott Laboratories. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Abbott price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Abbott Laboratories Daily Stochastic Oscillator ChartAbbott Laboratories Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Abbott Laboratories. The current cci is -83.31343521.

Abbott Laboratories Daily Commodity Channel Index (CCI) ChartAbbott Laboratories Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Abbott Laboratories. The current cmo is -30.30186041.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Abbott Laboratories Daily Chande Momentum Oscillator (CMO) ChartAbbott Laboratories Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Abbott Laboratories. The current willr is -74.84939759.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Abbott is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Abbott Laboratories Daily Williams %R ChartAbbott Laboratories Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Abbott Laboratories.

Abbott Laboratories Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Abbott Laboratories. The current atr is 1.86342479.

Abbott Laboratories Daily Average True Range (ATR) ChartAbbott Laboratories Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Abbott Laboratories. The current obv is 10,196,339.

Abbott Laboratories Daily On-Balance Volume (OBV) ChartAbbott Laboratories Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Abbott Laboratories. The current mfi is 48.29.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Abbott Laboratories Daily Money Flow Index (MFI) ChartAbbott Laboratories Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Abbott Laboratories.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-02STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Abbott Laboratories Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Abbott Laboratories based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.335
Ma 20Greater thanMa 50108.192
Ma 50Greater thanMa 100112.925
Ma 100Greater thanMa 200112.236
OpenGreater thanClose106.660
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Abbott with someone you think should read this too:
  • Are you bullish or bearish on Abbott? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Abbott? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Abbott Laboratories

I send you an email if I find something interesting about Abbott Laboratories.


Comments

How you think about this?

Leave a comment

Stay informed about Abbott Laboratories.

Receive notifications about Abbott Laboratories in your mailbox!